Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Moody's Corporation (MCO) vs Twist Bioscience Corp (TWST) Price & Performance

Moody's CorporationTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Moody's Corporation vs Twist Bioscience Corp — how do they compare? Moody's Corporation trades at $479.75 (market cap $82.52B), while Twist Bioscience Corp trades at $124.64 (market cap $7.72B). The key difference: Moody's Corporation is far larger — about 10.7× Twist Bioscience Corp's market cap, and Moody's Corporation pays a 0.86% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

MCOTWST
Market Cap
$82.52B$7.72B
Sector
FinancialsHealth
52-Week High
$539.61$124.88
52-Week Low
$412.23$24.16
Enterprise Value
$88.54B$7.65B
Dividend Yield
0.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Moody's Corporation

MCO trades at $477.84, showing minimal daily movement (-0.06%) amid a bearish technical signal. The company demonstrates strong fundamentals with 15% revenue growth in Q2 2026 and consistent earnings beats, achieving a 34.25% net income margin. Recent news highlights institutional repositioning into credit rating companies, with MCO benefiting from robust debt issuance and AI-related analytics demand.

Outlook remains positive with a $561.88 consensus price target (17.6% upside), though valuation multiples appear elevated. Key risks include competitive pressures and market sensitivity to credit cycles. The combination of strong profitability, analyst support (56% buy ratings), and strategic positioning in credit analytics supports a constructive view despite technical headwinds.

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $125.13, up 0.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q3 2026 revenue of $118.4 million, up 23% year-over-year, beating estimates, but posted a net loss. Revenue growth is strong, yet profitability remains elusive with negative margins. Recent news highlights an upsized $300 million public offering and expanding AI drug discovery pipeline.

Outlook is mixed: robust revenue growth and analyst optimism (78.57% buy ratings) support upside, but persistent losses, cash burn, and high valuation multiples pose significant risks. The stock's proximity to resistance at $126 suggests near-term volatility. Investors should weigh growth potential against financial sustainability concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Moody's Corporation

Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.

Read more on MCO

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST